CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Castration-resistant prostate cancer (CRPC) is an advanced stage of prostate cancer (PCa).
• Testosterone and its androgen receptor (AR) are crucial in CRPC progression.
• The role of CYP19A1, an enzyme influencing aromatase activity and potentially AR expression, in CRPC is not well understood.

Purpose of the Study:

• To investigate the expression and function of CYP19A1 in prostate cancer and CRPC.
• To explore the relationship between CYP19A1, AR expression, and CRPC cell behavior.
• To elucidate the regulatory role of BRD4 in the CYP19A1-AR pathway in CRPC.

Main Methods:

• Analysis of CYP19A1 expression in PCa and CRPC using public databases and clinical samples.
• In vitro and in vivo studies on the effects of CYP19A1 on CRPC cell invasion and proliferation.
• In vitro investigation of CYP19A1's testosterone metabolism.
• qRT-PCR and western blot to assess BRD4's effect on CYP19A1 and AR.
• IC50 value determination for JQ1's effect on cells.

Main Results:

• CYP19A1 was found to be downregulated in CRPC, correlating with reduced cell invasion/proliferation and increased AR expression.
• CYP19A1 suppresses AR expression, thereby affecting CRPC cell invasion and proliferation, potentially via testosterone metabolism.
• BRD4 inhibition using JQ1 increased CYP19A1 expression and decreased AR expression.
• BRD4 knockdown led to increased CYP19A1 and decreased AR expression.

Conclusions:

• CYP19A1 reduces CRPC cell invasion and proliferation by targeting AR, a process regulated by BRD4.
• CYP19A1 represents a potential therapeutic target for CRPC.
• Combined therapy involving CYP19A1 targeting and BRD4 inhibition may enhance CRPC treatment outcomes.